Skip to content

US · TXMD · DRUG MANUFACTURERS - SPECIALTY & GENERIC

TherapeuticsMD, Inc. (TXMD) intrinsic value and stock valuation

$1.71as of 2026-11-21 · Mkt cap 23.96M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

TherapeuticsMD, Inc. DCF and intrinsic value

InvestorsCraft values TXMD with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from TXMD’s statements →

TherapeuticsMD, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Drug Manufacturers - Specialty & Generic Boca Raton, FL 33431 therapeuticsmd.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$3.02M-45.9% 5y CAGRd
20112025
Net income
-$-570K
20112025
Free cash flow
$2.42M
20112025
Total equity
$26.9M
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$3.02M$1.76M$1.3M$70M$2.57M
Operating income-$-4.21M-$-4.76M-$-8.52M$1.19M-$-79.58M
Net income-$-570K-$-2.18M-$-10.28M$112M-$-172.41M
EPSd-$-49.27K-$-189.07K-$-984.67K$12.4M-$-21.66M
Operating cash flow$2.42M$730K-$-48.14M-$-4.08M-$-147.81M
Capital expenditure$0.00$0.00$48.1M-$-350K-$-30K
Free cash flow$2.42M$730K$0.00-$-4.43M-$-147.84M
Total assets$37.7M$38.8M$43.3M$90.5M$169.5M
Total debt$6.1M$7.17M$8.01M$8.76M$197.7M
Net debt-$-1.39M$2.12M$3.68M-$-29.31M$132.8M
Total equity$26.9M$27.4M$29.3M$35.1M-$-93.62M
Cash and short-term investments$7.48M$5.06M$4.33M$38.1M$64.9M
Income statement
20252024202320222021
Revenue$3.02M$1.76M$1.3M$70M$2.57M
Cost of revenue$1.19M$0.00$0.00$1.4M$1.4M
Gross profit$1.83M$1.76M$1.3M$68.6M$1.17M
Research and development expenses$0.00$0.00$0.00$0.00$0.00
Selling, general and administrative expenses$6.85M$6.1M$8.9M$56.7M$72.8M
Other expenses-$-810K$6.52M$9.82M$10.7M$8M
Operating expenses$6.04M$6.52M$9.82M$67.4M$80.8M
Cost and expenses$7.24M$6.52M$9.82M$68.8M$82.2M
Interest income$150K$140K$300K$0.00$0.00
Interest expense$10K$10K$200K$0.00$32.9M
Depreciation and amortization$1.19M$510K$440K$1.2M$740K
Ebitda-$-3.02M-$-2.98M-$-8.08M$11.9M-$-70.84M
Operating income-$-4.21M-$-4.76M-$-8.52M$1.19M-$-79.58M
Total other income/expenses, net$3.56M$2.42M$780K-$-120K$270K
Income before tax-$-650K-$-2.34M-$-7.74M$1.07M-$-79.31M
Income tax expense$0.00-$-30K-$-40K$0.00$0.00
Net income-$-570K-$-2.18M-$-10.28M$112M-$-172.41M
Weighted average shares outstanding$11.6M$11.5M$10.4M$9.03M$7.96M
Weighted average diluted shares outstanding$11.6M$11.5M$10.4M$9.03M$7.96M
Balance sheet
20252024202320222021
Cash and short-term investments$7.48M$5.06M$4.33M$38.1M$64.9M
Net receivables$3.52M$3.56M$3.09M$0.00$36.2M
Inventory$0.00$0.00$0.00$0.00$7.62M
Total current assets$14.5M$9.93M$11.8M$55.4M$119.5M
Property, plant and equipment, net$5.29M$6.1M$6.87M$7.66M$9.06M
Goodwill and intangible assets$3.76M$4.32M$6.1M$6.94M$7.14M
Long-term investments$0.00$16M$0.00$0.00$0.00
Total non-current assets$23.2M$28.9M$31.5M$35.1M$50M
Total assets$37.7M$38.8M$43.3M$90.5M$169.5M
Accounts payable$380K$260K$30K$2.16M$3.37M
Short-term debt$970K$1.63M$1.47M$1.39M$189.6M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$4.79M$5.17M$6.85M$46.8M$252.9M
Long-term debt$5.12M$5.54M$6.53M$7.37M$8.06M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$6M$6.29M$7.17M$8.48M$10.2M
Capital lease obligations$6.1M$5.54M$8.01M$8.76M$9.42M
Total liabilities$10.8M$11.5M$14M$55.3M$263.1M
Common stock$10K$10K$10K$10K$10K
Retained earnings-$-952.39M-$-951.82M-$-949.64M-$-939.36M-$-1.05B
Accumulated other comprehensive income (loss)$0.00$0.00-$0.00$0.00$0.00
Total equity$26.9M$27.4M$29.3M$35.1M-$-93.62M
Total investments$0.00$16M$0.00$0.00$0.00
Total debt$6.1M$7.17M$8.01M$8.76M$197.7M
Net debt-$-1.39M$2.12M$3.68M-$-29.31M$132.8M
Cash flow statement
20252024202320222021
Net income-$-650K-$-2.31M-$-7.7M$1.07M-$-79.31M
Depreciation and amortization$1.19M$510K$920K$1.19M$740K
Stock-based compensation$0.00$0.00$0.00$11.6M$0.00
Change in working capital$1.66M$1.66M-$-17.45M-$-4.09M$4.59M
Accounts receivable$0.00$0.00$0.00$0.00-$-4.33M
Inventory$0.00$0.00$0.00$0.00-$-710K
Accounts payable$120K$230K-$-2.13M-$-1.21M-$-1.06M
Net cash provided by operating activities$2.42M$730K-$-48.14M-$-4.08M-$-147.81M
Investments in property, plant and equipment$0.00$0.00$0.00-$-350K-$-2.22M
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$0.00$0.00$0.00$223.5M-$-2.22M
Common stock issued$0.00$0.00$3.15M$24.2M$184.7M
Common stock repurchased$0.00$0.00$0.00-$-38.66M$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$0.00$0.00$3.15M-$-235.21M$134.7M
Net change in cash$2.42M$730K-$-44.99M-$-15.8M-$-15.58M
Cash at end of period$7.48M$5.06M$4.33M$49.3M$64.9M
Operating cash flow$2.42M$730K-$-48.14M-$-4.08M-$-147.81M
Capital expenditure$0.00$0.00$48.1M-$-350K-$-30K
Free cash flow$2.42M$730K$0.00-$-4.43M-$-147.84M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About TherapeuticsMD, Inc.

        TherapeuticsMD, Inc. is a U.S.-based pharmaceutical company dedicated to women's health. Its marketed portfolio includes IMVEXXY, prescribed for moderate to severe dyspareunia; BIJUVA, a bio-identical hormone replacement therapy combining 17ß-estradiol and progesterone, used to alleviate moderate to severe vasomotor symptoms; and ANNOVERA, an innovative vaginal ring designed for contraception. In its developmental pipeline, TherapeuticsMD is advancing several preclinical candidates: TX-005HR, a transdermal cream containing only progesterone; TX-006HR, another transdermal cream formulated with both estradiol and progesterone; TX-007HR and TX-008HR, both experimental transdermal patches; and TX-009HR, an oral formulation of progesterone and estradiol. Beyond its core pharmaceutical offerings, the company produces and distributes both branded and generic prescription prenatal vitamins, notably under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 labels. Its prescription medications and prenatal vitamin lines reach consumers through established channels, including wholesale and retail pharmacy distributors. Established in 2008, TherapeuticsMD, Inc. maintains its corporate headquarters in Boca Raton, Florida.

        CEO
        Marlan D. Walker
        Employees
        1
        Beta
        0.59

        Explore

        Frequently asked questions

        What is the intrinsic value of TherapeuticsMD, Inc. (TXMD)?

        InvestorsCraft does not currently publish an intrinsic value for TXMD. How the IC value is calculated.

        Is TXMD undervalued?

        InvestorsCraft does not publish an undervaluation signal for TXMD at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.